Cellular processing of platinum anticancer drugs

Wang, Dong, Lippard, Stephen J.·2005·Nature Reviews Drug Discovery
DOI 10.1038/nrd1691

Cites (230)

Items 201–230 of 230

  1. The negative role of cyclin G in ATM-dependent p53 activation
    Takao Ohtsuka, Michael Rugaard Jensen, Hyung Gu Kim, Kyung‐Tae Kim, Sam W. Lee · 2004 · Oncogene
  2. Modulation of Cisplatinum Cytotoxicity by p53: Effect of p53-Mediated Apoptosis and DNA Repair
    Jianguo Fan, Joseph R. Bertino · 1999 · Molecular Pharmacology
  3. Platinum(IV) Anticancer Complexes
    Matthew D. Hall, Rachael C. Dolman, Trevor W. Hambley · 2004 · CRC Press eBooks
  4. Requirement of caspase-mediated cleavage of c-Abl during stress-induced apoptosis
    Nikolaus Machuy, Krishnaraj Rajalingam, Thomas Rudel · 2003 · Cell Death and Differentiation
  5. Antitumor Active Trans-Platinum Compounds
    Giovanni Natile, Mauro Coluccia · 2004 · CRC Press eBooks
  6. Cisplatin Sensitivity in Hmgb1−/− and Hmgb1+/+ Mouse Cells
    Min Wei, Olga V. Burenkova, Stephen J. Lippard · 2003 · Journal of Biological Chemistry
  7. DNA mismatch repair and acquired cisplatin resistance in E. coli and human ovarian carcinoma cells
    Andrew J. Massey, Judith Offman, Peter Macpherson · 2002 · DNA repair
  8. Regulation of Platinum-Compound Cytotoxicity by the c-Jun N-Terminal Kinase and c-Jun Signaling Pathway in Small-Cell Lung Cancer Cells
    Valérie Levresse, Lindsay A. Marek, Deborah Blumberg · 2002 · Molecular Pharmacology
  9. Multiple States of Stalled T7 RNA Polymerase at DNA Lesions Generated by Platinum Anticancer Agents
    Yongwon Jung, Stephen J. Lippard · 2003 · Journal of Biological Chemistry
  10. Modulation of PI3K/Akt pathway by E1a mediates sensitivity to cisplatin
    Juan Guinea Viniegra, Javier Hernández‐Losa, Victor Javier Sanchez-Arevalo Lobo, Carlos Parada Cobo, V. Fernández‐Soria, Santiago Ramón y Cajal, Ricardo Sánchez‐Prieto · 2002 · Oncogene
  11. Cisplatin and UV Radiation Induce Activation of the Stress-Activated Protein Kinase p38γ in Human Melanoma Cells
    Marie‐Jeanne Pillaire, Ángel R. Nebreda, Jean-Marie Darbon · 2000 · Biochemical and Biophysical Research Communications
  12. Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells
    Nanna Claij, Hein te Riele · 2004 · Oncogene
  13. Pharmacological Modulation of Poly(ADP-ribose) Polymerase-Mediated Cell Death: Exploitation in Cancer Chemotherapy
    Paul Nguewa, Miguel Angel Fuertes, Carlos Alonso‐Moreno, José M. Peréz · 2003 · Molecular Pharmacology
  14. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line
    Patrick G. Johnston, F. Geoffrey, James Drake · 1996 · European Journal of Cancer
  15. A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells
    Yasunobu Kanamori, Junzo Kigawa, Y Minagawa · 1998 · European Journal of Cancer
  16. Mechanisms for Cisplatin-FUra Synergism and Cisplatin Resistance in Human Ovarian Carcinoma Cells both in vitro and in vivo
    Kevin J. Scanlon, Yuzhi Lu, Mohammed Kashani–Sabet · 1988 · Advances in experimental medicine and biology
  17. c-Abl tyrosine kinase can mediate tumor cell apoptosis independently of the Rb and p53 tumor suppressors
    Stefan Theis, Klaus Roemer · 1998 · Oncogene
  18. p53 is phosphorylated at the carboxyl terminus and promotes the differentiation of human HaCaT keratinocytes
    Jesús María Paramio, Carmen Segrelles, Sonia La�n, Elena G�mez-Casero, David Philip Lane, Ellen Birgitte Lane, JoséL. Jorcano · 2000 · Molecular Carcinogenesis
  19. Effect of DNA conformation on cisplatin adduct formation
    Glenn J. Bubley, Jian Yu Xu, Nadav Kupiec, Dennis A. Sanders, Francine M. Foss, Mary O'Brien, Yasu Emi, Beverly A. Teicher, Steven R. Patierno · 1996 · Biochemical Pharmacology
  20. Interaction of cis-diamminedichloroplatinum (II) to chromatin
    Maria Foka, Jacques Paoletti · 1986 · Biochemical Pharmacology
  21. cis-Diamminedichloroplatinum (II) modified chromatin and nucleosomal core particle
    Jeffrey J. Hayes, William M. Scovell · 1991 · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression
  22. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner
    Owen James Sansom, Neil J. Toft, Douglas J. Winton · 2001 · Oncogene
  23. Effect of p53 Gene Transfer and Cisplatin in a Peritonitis Carcinomatosa Model with p53-Deficient Ovarian Cancer Cells
    Junzo Kigawa, Shinya Sato, Muneaki Shimada · 2002 · Gynecologic Oncology
  24. Copper(II) protects yeast against the toxicity of cisplatin independently of the induction of metallothionein and the inhibition of platinum uptake
    Kazuaki Ohashi, Kazuki Kajiya, Sachiko Inaba · 2003 · Biochemical and Biophysical Research Communications
  25. cis- and trans-Diamminedichloroplatinum(II) Interstrand Cross-Linking of a Defined Sequence Nucleosomal Core Particle,
    Julie T. Millard, Erin E. Wilkes · 2000 · Biochemistry
  26. Sensitivity of anticancer drugs in NIH3T3' cells transfected with oncogenes accompanied by pSV2neo vector.
    Xianshu Gao, Junichi Asaumi, Shoji Kawasaki · 1996 · PubMed
  27. The DNA-binding domain of human c-Abl tyrosine kinase promotes the interaction of a HMG chromosomal protein with DNA
    Marie‐Hélène David‐Cordonnier, Dominique Payet‐Bornet, Jean-Claude D'Halluin · 1999 · Nucleic Acids Research
  28. The chemotherapy of head and neck cancer
    P H de Mulder · 1999 · Anti-Cancer Drugs
  29. Mutagenesis of the HMGB (high-mobility group B) protein Cmb1 (cytosine-mismatch binding 1) of Schizosaccharomyces pombe: effects on recognition of DNA mismatches and damage
    Christophe Kunz, Karin Zurbriggen, Oliver Fleck · 2003 · Biochemical Journal
  30. cis-Diamminedichloroplatinum (II) modified chromatin and nucleosomal core particle probed with DNase I
    Jeffrey J. Hayes, William M. Scovell · 1991 · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression